3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Conditions
Breast Neoplasms
10
Neoplasms
7
Anxiety Disorders
6
Depression
5
Uterine Cervical Neoplasms
2
Smoking Cessation
2
Lymphoma
2
Colorectal Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Dysplasia
1
Stress, Psychological
1
Stage III Gynecologic Cancer
1
Smoking
1
Skin Neoplasms
1
Psychological Well-Being
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parasomnias
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Motor Activity
1
Melanoma
1
Medically Unexplained Symptoms
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Interventions
Cyclophosphamide
444
Rituximab
401
Etoposide
224
Vincristine
215
Doxorubicin
201
Filgrastim
200
Prednisone
176
Cytarabine
159
Radiotherapy
152
fludarabine phosphate
147
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
129
Melphalan
127
fludarabine
115
Busulfan
99
Dexamethasone
93
Tacrolimus
75
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
71
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
62
Cyclosporine
62
Bendamustine Hydrochloride
62
Lenalidomide
60
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma
×
Mindfulness
×
Clear all
NCT06063603
2025-09-18
ASCENT
Mayo Clinic
Phase NA
Completed
51 enrolled
8 charts
NCT02272751
2019-02-20
REIL
St George's, University of London
Phase NA
Completed
41 enrolled